4.7 Article

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

期刊

LEUKEMIA
卷 27, 期 3, 页码 650-660

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2012.285

关键词

PI3K; NOTCH; c-MYC; T-cell

资金

  1. NIHR Biomedical Research Centres funding scheme of the UK Department of Health
  2. Leukaemia and Lymphoma Research, UK
  3. Kay Kendall Leukaemia Fund
  4. Medical Research Council UK
  5. Tapner ALL Research Fund

向作者/读者索取更多资源

PI3K, mTOR and NOTCH pathways are frequently dysregulated in T-cell acute lymphoblastic leukaemia (T-ALL). Blockade of PI3K and mTOR with the dual inhibitor PI-103 decreased proliferation in all 15 T-ALL cell lines tested, inducing cell death in three. Combined PI3K/mTOR/NOTCH inhibition (with a gamma-secretase inhibitor (GSI)) led to enhanced cell-cycle arrest and to subsequent cell death in 7/11 remaining NOTCH mutant cell lines. Commitment to cell death occurred within 48-72 h and was maximal when PI3K, mTOR and NOTCH activities were inhibited. PI-103 addition led to upregulation of c-MYC, which was blocked by coincubation with a GSI, indicating that PI3K/mTOR inhibition resulted in activation of the NOTCH-MYC pathway. Microarray studies showed a global increase in NOTCH target gene expression upon PI3K/mTOR inhibition. NOTCH-MYC-induced resistance to PI3K/nnTOR inhibition was supported by synergistic cell death induction by PI-103 and a small molecule c-MYC inhibitor, and by reduction of the cytotoxic effect of PI-103 + GSI by c-MYC overexpression. These results show that drugs targeting PI3K/mTOR can upregulate NOTCH-MYC activity, have implications for the use of PI3K inhibitors for the treatment of other malignancies with activated NOTCH, and provide a rational basis for the use of drug combinations that target both the pathways. Leukemia (2013) 27, 650-660; doi:10.1038/leu.2012.285

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish

Evisa Gjini, Chang-Bin Jing, Ashley T. Nguyen, Deepak Reyon, Emma Gans, Michiel Kesarsing, Joshua Peterson, Olga Pozdnyakova, Scott J. Rodig, Marc R. Mansour, Keith Joung, A. Thomas Look

DISEASE MODELS & MECHANISMS (2019)

Article Oncology

The AAA plus ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia

Elena Armenteros-Monterroso, Lu Zhao, Luca Gasparoli, Tony Brooks, Kerra Pearce, Marc R. Mansour, Joost H. A. Martens, Jasper de Boer, Owen Williams

LEUKEMIA (2019)

Article Hematology

Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress

Richard Burt, Aditi Dey, Sarah Aref, Melanie Aguiar, Ayse Akarca, Katharine Bailey, William Day, Steven Hooper, Amy Kirkwood, Kristina Kirschner, Soo-Wah Lee, Cristina Lo Celso, Jiten Manji, Marc R. Mansour, Teresa Marafioti, Rachel J. Mitchell, Robert C. Muirhead, Kenton Cheuk Yan Ng, Constandina Pospori, Ignazio Puccio, Krisztina Zuborne-Alapi, Erik Sahai, Adele K. Fielding

Review Cell Biology

The role of noncoding mutations in blood cancers

Sunniyat Rahman, Marc R. Mansour

DISEASE MODELS & MECHANISMS (2019)

Letter Hematology

In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation

Catherine Hockings, Satyen Gohil, Robin Dowse, Yvette Hoade, Marc R. Mansour, Rosemary E. Gale, David C. Linch, Anupama Rao, Elspeth M. Payne

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Article Oncology

EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress

Theresa E. Leon, Tanya Rapoz-D'Silva, Cosetta Bertoli, Sunniyat Rahman, Michael Magnussen, Brian Philip, Nadine Farah, Simon E. Richardson, Sara Ahrabi, Jose Afonso Guerra-Assuncao, Rajeev Gupta, Elisabeth P. Nacheva, Stephen Henderson, Javier Herrero, David C. Linch, Robertus A. M. de Bruin, Marc R. Mansour

CANCER DISCOVERY (2020)

Letter Hematology

Successful remission induction therapy with gilteritinib in a patient withde novo FLT3-mutated acute myeloid leukaemia and severe COVID-19

Andrew J. Wilson, Ethan Troy-Barnes, Maryam Subhan, Fiona Clark, Rajeev Gupta, Adele K. Fielding, Panagiotis Kottaridis, Marc R. Mansour, Jenny O'Nions, Elspeth Payne, Naina Chavda, Robert Baker, Kirsty Thomson, Asim Khwaja

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Letter Hematology

CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy

Sarah Leong, Sarah Inglott, Foteini Papaleonidopoulou, Karen Orfinada, Philip Ancliff, Jack Bartram, Ben Carpenter, Adele K. Fielding, Sara Ghorashian, Victoria Grandage, Rajeev Gupta, Rachael Hough, Asim Khwaja, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Ajay Vora, Marc R. Mansour, David O'Connor

BLOOD ADVANCES (2020)

Letter Oncology

Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma

Thomas A. Fox, Ben Carpenter, Mary Taj, Martha Perisoglou, Emma Nicholson, Anna Castleton, Johnathon Elliot, Ben Uttenthal, Callum Wright, Richard Halsey, Asim Khwaja, Victoria Grandage, Marc R. Mansour, Adele K. Fielding, Rachael Hough

LEUKEMIA & LYMPHOMA (2021)

Review Hematology

Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia

Rachael Pocock, Nadine Farah, Simon E. Richardson, Marc R. Mansour

Summary: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of T-cell progenitors that remains challenging to treat despite improvements in survival outcomes over the past 50 years. Relapsed and refractory cases are particularly difficult to manage, and T-ALL is proving to be a more challenging immunotherapeutic target compared to B-ALL. Understanding the basic biology of T-ALL is crucial in repurposing established treatments and developing novel therapeutic approaches.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Letter Oncology

Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols

Mary M. Taj, Anthony V. Moorman, Lina Hamadeh, Arnaud Petit, Vahid Asnafi, Fanny Alby-Laurent, Ajay Vora, Marc R. Mansour, Rosemary Gale, Sylvie Chevret, John Moppett, Andre Baruchel, Elizabeth Macintyre

LEUKEMIA (2022)

Article Biochemistry & Molecular Biology

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Shuning He, Mark W. Zimmerman, Hillary M. Layden, Alla Berezovskaya, Julia Etchin, Megan W. Martel, Grace Thurston, Chang-Bin Jing, Ellen van Rooijen, Charles K. Kaufman, Scott J. Rodig, Leonard I. Zon, E. Elizabeth Patton, Marc R. Mansour, A. Thomas Look

Summary: Loss of the NF1 tumor suppressor gene can lead to aggressive melanomas with a high risk of treatment failure. This study established a zebrafish model of NF1-mutant melanomas harboring PTEN loss and demonstrated that mTOR inhibitors and a three-drug combination can potently induce apoptosis in NF1/PTEN-deficient melanoma cells, supporting the need for early-stage clinical trials in patients.

ONCOGENE (2021)

Review Medicine, General & Internal

Therapeutic targeting of undruggable MYC

Victor Llombart, Marc R. Mansour

Summary: c-MYC plays a crucial role in regulating gene expression and is involved in tumor initiation and maintenance. Inhibition of MYC shows promising anti-proliferative effects and tumor regression, making it a potential therapeutic target for cancer treatment.

EBIOMEDICINE (2022)

Article Hematology

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Paul M. Maciocia, Patrycja A. Wawrzyniecka, Nicola C. Maciocia, Amy Burley, Thaneswari Karpanasamy, Sam Devereaux, Malika Hoekx, David O'Connor, Theresa Leon, Tanya Rapoz-D'Silva, Rachael Pocock, Sunniyat Rahman, Giuseppe Gritti, Diana C. Yanez, Susan Ross, Tessa Crompton, Owen Williams, Lydia Lee, Martin A. Pule, Marc R. Mansour

Summary: CCR9 expression is found in the majority of T-ALL cases, making it a potential target for CAR-T cell therapy. CAR-T cells targeting CCR9 can effectively inhibit leukemia cell proliferation without harming healthy T cells, providing a promising treatment strategy for T-ALL.
Article Oncology

Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia

Juliette Roels, Morgan Thenoz, Mattias Landfors, Stien De Coninck, Lisa Demoen, Lien Provez, Anna Kuchmiy, Steven Strubbe, Lindy Reunes, Tim Pieters, Filip Matthijssens, Wouter Van Loocke, Busra Erarslan-Uysal, Paulina Richter-Pechanska, Ken Declerck, Tim Lammens, Barbara De Moerloose, Dieter Deforce, Filip Van Nieuwerburgh, Laurence C. Cheung, Rishi S. Kotecha, Marc R. Mansour, Bart Ghesquiere, Guy Van Camp, Wim Vanden Berghe, Jerzy R. Kowalczyk, Tomasz Szczepanski, Utpal P. Dave, Andreas E. Kulozik, Steven Goossens, David J. Curtis, Tom Taghon, Malgorzata Dawidowska, Sofie Degerman, Pieter Van Vlierberghe

BLOOD CANCER DISCOVERY (2020)

暂无数据